1-benzyl-4-(4-methylphenyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-benzyl-4-(4-methylphenyl)piperazine
• 英文别名: 1-benzyl-4-(p-tolyl)piperazine
• 化学式: C₁₈H₂₂N₂
• 分子量: 266.386
• InChiKey: RJAPZKOCYUHSBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  氯化苄 在 copper(l) chloride 、 lithium tert-butoxide 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 14.25h， 生成 1-benzyl-4-(4-methylphenyl)piperazine
  参考文献：
  名称：

  N-烷基-N'-芳基或烯基哌嗪的合成：在芳基和烯基三氟甲磺酸酯和DABCO存在下，铜催化的C-N交叉偶联

  摘要：

  不对称哌嗪是许多药物的关键成分。鉴于将芳基和烷基基序选择性引入哌嗪并不总是那么简单，因此1,4-二氮杂双环[2.2.2]辛烷的直接芳基化和烯基化将消除与这些目标分子制备相关的低效率。我们利用卤代烷，芳基或烯基三氟甲磺酸酯和1,4-二氮杂双环[2.2.2]辛烷来合成N-烷基-N'-芳基或烯基哌嗪。在NMP中使用CuCl，t- BuOLi来确定最佳条件。烯基三氟甲磺酸盐需要N，N'-二甲基乙二胺和更高的温度提供所需的交叉偶联产物。在最佳反应条件下，成功地偶联了具有缺电子和富电子基团的底物。

  DOI：

  10.1002/hlca.201700082

文献信息

• One‐Pot Transfer Hydrogenation Reductive Amination of Aldehydes and Ketones by Iridium Complexes “on Water”
  作者：Lu Ouyang、Yanping Xia、Jianhua Liao、Renshi Luo

  DOI：10.1002/ejoc.202001097

  日期：2020.10.31

  An efficient and practical one-pot transfer hydrogenation reductive amination of aldehydes and ketones with amines has been developed by using iridium complexes as catalysts and formic acid as hydrogen source in aqueous, providing an environmental friendly methodology for the construction of a wide range of functionalized amine compounds in excellent yields (80%~95%) This effective methodology can

  以铱配合物为催化剂，甲酸为氢源，在水溶液中开发了一种高效实用的醛酮与胺的一锅转移加氢还原胺化反应，为构建广泛的功能化胺提供了一种环境友好的方法。高产率的化合物 (80%~95%) 这种有效的方法可以放大到克以 0 1 mol% 催化剂负载，也可用于合成药物，如 Meclizine
• [EN] SUBSTITUTED 4-METHYL-PYRROLO[1.2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY<br/>[FR] COMPOSÉS DE 4-MÉTHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE SUBSTITUÉ ET LEURS UTILISATIONS POUR MODULER L'ACTIVITÉ DE LA GLUCOCÉRÉBROSIDASE
  申请人：UNIV NORTHWESTERN

  公开号：WO2017004408A1

  公开（公告）日：2017-01-05

  Disclosed are new small molecules having a 4-methylpyrrrolo[l,2-a]pyrimidine- 8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

  揭示了具有4-甲基吡咯并[1,2-a]嘧啶-8-羧酰胺核结构的新型小分子及其用途，用于调节葡萄糖乙酰硫脂酶活性。还揭示了包含这些小分子的药物组合物，可用于治疗与葡萄糖乙酰硫脂酶活性相关的疾病或疾病，包括神经系统疾病和障碍，如高雪氏病和帕金森病。这些小分子可能含有荧光团或与荧光团结合，以制备用于高通量筛选方法中的荧光探针，以通过荧光极化识别葡萄糖乙酰硫脂酶活性的新调节剂。
• SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES
  申请人：Hoffmann Matthias

  公开号：US20110201608A1

  公开（公告）日：2011-08-18

  The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R 1 denotes a group A selected from among —O—R 3 , —NR 3 R 4 , —CR 3 R 4 R 5 , -(ethyne)-R 3 , —S—R 3 , —SO—R 3 and SO 2 —R 3 or R 1 denotes a group B selected from among C 6-10 -aryl, five- to ten-membered, mono- or bicyclic heteroaryl with 1-3 heteroatoms selected independently of one another from among N, O and S; while this heteroaryl is linked to the structure according to formula 1 via either a C atom or an N atom, three- to ten-membered, mono- or bicyclic, saturated or partially saturated heterocyclic group with 1-3 heteroatoms selected independently of one another from among N, O and S, while this heterocyclic group is linked to the structure according to formula 1 via either a C atom or an N atom, and 5- to 11-membered spiro group which may optionally contain 1, 2 or 3 heteroatoms selected independently of one another from among N, O and S, while this spiro group is linked to the structure according to formula 1 via either a C atom or an N atom, while this group B may optionally be substituted as described in claim 1 and wherein R 2 is and R 3 , R 4 , R 5 , R 6 , R 6′ , R 7 , R 8 , R 9 , R 10 , V, n and m may have the meanings given in claim 1 , as well as pharmaceutical compositions containing these compounds.

  该发明涉及公式1的新取代萘啉类化合物，以及其药理学上可接受的盐、对映体、对映异构体、外消旋体、水合物或溶剂合物，其中R1表示从以下选取的A基团，包括—O—R3、—NR3R4、—CR3R4R5、-(乙炔)-R3、—S—R3、—SO—R3和SO2—R3，或R1表示从以下选取的B基团，包括C6-10-芳基、含有1-3个异原子（N、O和S）的五至十元杂环芳基，而此杂环芳基通过碳原子或氮原子与公式1中的结构连接，含有1-3个异原子（N、O和S）的三至十元杂环饱和或部分饱和环族基团，而此杂环基团通过碳原子或氮原子与公式1中的结构连接，以及可能含有1、2或3个异原子（N、O和S）的五至十一元螺环基团，而此螺环基团通过碳原子或氮原子与公式1中的结构连接，其中该B基团可以选择地按照权利要求1中所述进行取代，R2为，R3、R4、R5、R6、R6′、R7、R8、R9、R10、V、n和m的含义如权利要求1中所述，以及含有这些化合物的药物组合物。
• Inhibitors of Histone Deacetylase
  申请人：Moradei Oscar

  公开号：US20080132459A1

  公开（公告）日：2008-06-05

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的方法。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。
• Synthesis of N-alkyl-N′-aryl-piperazines via copper-catalyzed C–N bond formation
  作者：Issa Yavari、Mohammad J. Bayat、Majid Ghazanfarpour-Darjani

  DOI：10.1016/j.tetlet.2014.08.045

  日期：2014.10

  An efficient copper-catalyzed tandem synthesis of N-alkyl-N'-aryl-piperazines from 1,4-diazabicyclo[2.2.2]octane, alkyl halides, and aryl halides in the presence of copper(I) iodide and potassium tert-butoxide in DMSO is described. (C) 2014 Published by Elsevier Ltd.